Ferring Reveals Initial Findings From Key Phase 3 Study on SI-6603 (condoliase) for Lumbar Disc Herniation at ASPN 2024.

Asciminib was approved by the U.S. Food and Drug Administration (FDA) on October 29, 2021.

Lexeo Therapeutics Shares Encouraging Early Phase 1/2 Results of LX2006 for Friedreich Ataxia Cardiomyopathy Treatment.

celecoxib and tramadol, marketed under the brand name Seglentis, received FDA approval on October 15, 2021.

Camurus reveals successful Phase 3 outcomes for the ACROINNOVA 2 trial of octreotide SC depot (CAM2029) in individuals with acromegaly.

Maralixibat, marketed under the brand name Livmarli, received FDA approval on September 29, 2021.

AbbVie Files for Regulatory Approval of Upadacitinib (RINVOQ®) with FDA and EMA for Treatment of Giant Cell Arteritis.

atogepant is FDA approved. Atogepant, marketed under the brand name Qulipta, received FDA approval on September 28, 2021.

YolTech Therapeutics has announced the successful enrollment of the inaugural patient in the Phase I clinical trial of YOLT-201.

Tisotumab vedotin (Tivdak) received accelerated approval from the US Food and Drug Administration (FDA) on September 20, 2021.

Olatec Therapeutics, Inc., a pioneer in the field of selective NLRP3 inhibitors, revealed that individuals with type 2 diabetes mellitus and associated diabetic complications are currently being recruited

Mobocertinib (Exkivity) received accelerated approval from the US Food and Drug Administration (FDA) on September 15, 2021.